Liposomes loaded with a dirhenium compound and cisplatin: preparation, properties and improved in vivo anticancer activity

References

• Abraham SA, Edwards K, Karlsson G, et al. (2002). Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta Biomembr 1565:41–54
   PubMed Web of Science ®Google Scholar
• Abraham SA, McKenzie C, Masin D, et al. (2004). In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 10:728–38
   PubMed Web of Science ®Google Scholar
• Adams DJ, Sandvold ML, Myhren F, et al. (2008). Anti proliferative activity of ELACYT™ (CP-4055) in combination with cloretazine (VNP40101M) idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leuk Lymphoma 49:786–97
   PubMed Web of Science ®Google Scholar
• Almgren M, Edwards K, Karlsson G. (2000). Cryo transmission electron microscopy of liposomes and related structures. Colloids Surf A 174:3–21
   Web of Science ®Google Scholar
• Batist G, Gelmon KA, Chi KN, et al. (2009). Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res 15:692–700
   PubMed Web of Science ®Google Scholar
• Boulikas T. (2004). Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 12:3–12
   PubMed Web of Science ®Google Scholar
• Chen H, Pazicni S, Kret NL, et al. (2009). Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment. Angew Chem Int Ed 48:9295–9
   PubMed Web of Science ®Google Scholar
• Chifotides HT, Dunbar KR. (2005). Interactions of metal-metal-bonded antitumor active complexes with DNA fragments and DNA. Acc Chem Res 38:146–56
   PubMed Web of Science ®Google Scholar
• Chifotides HT, Fu PKL, Dunbar KR, Turro C. (2004). Effect of equatorial ligands of dirhodium(II,II) complexes on the efficiency and mechanism of transcription inhibition in vitro. Inorg Chem 43:1175–83
   Google Scholar
• Chou TC. (2006). Theoretical basis, experimental design, and computerized simulation of synergsim and antagonism in drug combination studies. Pharmacol Rev 58:621–81
   PubMed Web of Science ®Google Scholar
• Clarke MJ, Zhu F, Frasca DR. (1999). Non-platinum chemotherapeutic metallopharmaceuticals. Chem Rev 99:2511–34
   PubMed Web of Science ®Google Scholar
• Dicko A, Mayer LD, Tardi PG. (2010). Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin Drug Deliv 7:1329–41
   PubMed Web of Science ®Google Scholar
• Facy O, Radais F, Ladoire S, et al. (2011). Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murine model of peritoneal carcinomatosis. J Exp Clin Cancer Res 30:4. doi:10.1186/1756-9966-30-4
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Lancet JE, Kolitz JE, et al. (2007). Phase I study of a liposomal carrier (CPX-351) containing an optimized, synergistic, fixed molar ratio of cytarabine and daunorubicin in advanced leukemias and myelodysplastic syndromes. Blood (ASH Annual Meeting Abstracts) New York 110(11):900
   Google Scholar
• Guo Z, Sadler PJ. (1999). Metals in medicine. Angew Chem Int Ed 38:1512–31
   PubMed Web of Science ®Google Scholar
• Hanigan MH, Lykissa ED, Townsend DM, et al. (2001). γ-Glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. Am J Pathol 159:1889–94
   PubMed Web of Science ®Google Scholar
• Harasym TO, Tardi PG, Johnstone SA, Lawrence DM. (2007). Fixed drug ratio liposome formulations of combination cancer therapeutics. In: Gregoriadis G, ed. Liposome technology. Interactions of liposomes with biological milieu, 3rd ed. New York: Informa Healthcare, Inc., 25–46
   Google Scholar
• Jakupec MA, Galanski M, Arion VB, et al. (2008). Antitumour metal compounds: more than theme and variations. Dalton Trans 2:183–94
   PubMed Web of Science ®Google Scholar
• Jensen M, Bjerring M, Nielsen NC, Nerdal W. (2010). Cisplatin interaction with phosphatidylserine bilayer studied by solid-state NMR spectroscopy. J Biol Inorg Chem 15:213–23
   Google Scholar
• Jensen M, Nerdal W. (2008). Anticancer cisplatin interactions with bilayers of total lipid extract from pig brain: a 13C, 31P and 15N solid state NMR study. Eur J Pharm Sci 34:140–8
   Google Scholar
• Jiang M, Liu Z, Xiang Y, et al. (2011). Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. BMC Cancer 11:54
   Google Scholar
• Kilic U, Kilic E, Tuzcu Z, et al. (2013). Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway. Nutr Metab 10:7. doi:10.1186/1743-7075-10-7
   Google Scholar
• Lau JK-C, Deubel DV. (2006). Hydrolysis of the anticancer drug cisplatin: pitfalls in the interpretation of quantum chemical calculations. J Chem Theory Comput 2:103–6
   Google Scholar
• Lee MS. (2012). Systematic prioritization of cancer combination therapies: are we really on target? Future Med Chem 4:387–9
   Google Scholar
• Lee RJ. (2006). Liposomal delivery as a mechanism to enhance synergism between anticancer drugs. Mol Cancer Ther 5:1639–40
   Google Scholar
• Lu Y, Cederbaum AI. (2006). Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicol Sci 89:515–23
   PubMed Web of Science ®Google Scholar
• Mayer L, Harasym T, Tardi P, et al. (2006). Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 5:1854–63
   PubMed Web of Science ®Google Scholar
• Miller RP, Tadagavadi RK, Ramesh G, Reeves W.B. (2010). Mechanisms of cisplatin nephrotoxicity. Toxins 2:2490–518
   PubMed Web of Science ®Google Scholar
• Oliynik S.A, Shtemenko NI, Gorchakova NO. (2001). Toxicology of rhenium compounds: a glance on the problem. Contemporary Prob Toxicol 1:3–12
   Google Scholar
• Rattan R, Graham RP, Maguire JL, et al. (2011). Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 13:483–91
   PubMed Web of Science ®Google Scholar
• Saleena UV, Athiyaman MS, Donald F, et al. (2012). Evaluation of urinary tubular enzymes for the detection of early kidney injury due to cisplatin chemotherapy. Int J Biol Med Res 3:2241–6
   Google Scholar
• Santos ND, Mayer LD, Abraham SA, et al. (2002). Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta Biomembr 1561:188–201
   Google Scholar
• Shen DW, Pouliot LM, Hall MD, Gottesman MM. (2012). Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 64:706–21
   PubMed Web of Science ®Google Scholar
• Sherman SI. (2010). Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol 22:464–8
   PubMed Web of Science ®Google Scholar
• Shtemenko AV, Collery P, Shtemenko NI, et al. (2009). Synthesis, characterization, in vivo antitumor properties of the cluster rhenium compound with GABA ligands and its synergism with cisplatin. Dalton Trans 26:5132–6
   Google Scholar
• Shtemenko N, Collery P, Shtemenko A. (2007). Dichlorotetra-μ-isobutyratodirhenium(III): enhancement of cisplatin action and RBC-stabilizing properties. Anticancer Res 27:2487–92
   Google Scholar
• Shtemenko NI, Babiy SA, Chifotides HT, et al. (2013). Synthesis, X-ray structure, interactions with DNA, remarkable in vivo tumor growth suppression and nephroprotective activity of cis-tetrachloro-dipivalato dirhenium(III). J Inorg Biochem 129:127–34
   PubMed Web of Science ®Google Scholar
• Shtemenko NI, Zabitskaya ED, Berzenina OV, et al. (2008). Liposomal forms of rhenium cluster compounds: enhancement of biological activity. Chem Biodivers 5:1660–7
   Google Scholar
• Shtemenko OV, Zeleniuk MA, Shtemenko NI, Verbyts'ka YC. (2002). Spectrophotometric study of the interaction between rhenium complexes and phosphatidylcholine during liposome formation. Ukr Biokhim Zh 74:91–6
   Google Scholar
• Sorasaenee K, Fu PKL, Angeles-Boza AM, et al. (2003). Inhibition of transcription in vitro by anticancer active dirhodium(II) complexes. Inorg Chem 42:1267–71
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP. (2010). Liposomal cisplatin: a new cisplatin formulation. Anti-Cancer Drugs 21:732–36
   PubMed Web of Science ®Google Scholar
• Stefanowicz J, Owczuk R, Iżycka-Świeszewska E, et al. (2011). Nephrotoxicity of platinum derivatives in children – a review of the literature. Contemporary Oncol 15:74–9
   Google Scholar
• Sun RW, Ma DL, Wong EL, Che CM. (2007). Some uses of transition metal complexes as anti-cancer and anti-HIV agents. Dalton Trans 43:4884–92
   PubMed Web of Science ®Google Scholar
• Tardi PG, Santos ND, Harasym TO, et al. (2009). Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther 8:2266–75
   PubMed Web of Science ®Google Scholar
• Tekola R. (2007). Liposomal cisplatin: lipoplatin. EJOP 1:15–20
   Google Scholar